Actively Recruiting
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
Led by Shanxi Bethune Hospital · Updated on 2025-08-14
110
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Aplastic anemia (AA) is a rare bone marrow failure syndrome with an annual incidence of about 0.74/100,000, affecting all ages but more common in the elderly. It's divided into congenital and acquired forms, with the latter being more prevalent. The primary acquired form is linked to T lymphocyte activation and genetic factors. The best treatment is allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a near 90% cure rate. Sibling allo-HSCT is ideal but finding a match is challenging. For those who relapse after immunosuppressive therapy, haploidentical HSCT is a viable option despite risks like graft failure and GVHD. Advances in transplantation have made haplo-HSCT's efficacy comparable to other methods. Recent studies suggest co-transplantation with umbilical cord blood cells can improve outcomes by hastening hematopoietic recovery and prognosis. Our study will evaluate the feasibility and safety of this approach in AA treatment, comparing it to sibling fully matched transplantation, with a focus on infection rates, GVHD incidence, TRM, and EFS, aiming to enhance treatment practices and benefit patients and the medical industry.
CONDITIONS
Official Title
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 6 and 75 years
- Diagnosed with Severe Aplastic Anemia (SAA), Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA), or Paroxysmal nocturnal hemoglobinuria (PNH) acquired clonal-aplastic anemia according to 2022 Chinese guidelines
- Suitable for allogeneic hematopoietic stem cell transplantation
- Signed informed consent or consent given by legally acceptable representative
You will not qualify if you...
- Any abnormality in vital signs such as heart rate, respiratory rate, or blood pressure
- Any condition deemed unsuitable for the trial by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanxi Bethune Hospital
Taiyuan, Shanxi, China, 030000
Actively Recruiting
Research Team
T
Tao Wang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here